CRISPR Therapeutics AG Aktie News

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of certain drugs in the U.S. and investing in local manufacturing efforts. This deal lifted not only Pfizer, but also much of the healthcare sector, especially the company's drugmaking peers, as Wall...

ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, taking place October 7-10, 2025. The presenta...

You don't have to invest a fortune to get involved in an industry that could offer your portfolio growth along with safety. I'm talking about the field of healthcare, specifically companies that develop therapeutics.

Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate the kind of returns over the long run that will help you achieve that goal -- in fact, most probably won't.

Crispr Therapeutics AG remains undervalued despite recent stock volatility and slow Casgevy commercial uptake, with long-term potential intact. Casgevy's strong clinical data and broad approvals are tempered by complex administration and high costs, but demand remains robust and efficiency is improving. CRSP's pipeline—including allogeneic CAR-T, in vivo gene editing, and diabetes programs—offe...

Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase her bet -- at a great price.

ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that a late-breaking oral presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 in vivo gene editing therapy, CTX310™, targeting ang...

Last week, the SPDR S&P Biotech ETF surged 6%.